AbbVie gains attention as healthcare rotation highlights Skyrizi, Rinvoq, immunology growth, and portfolio strength beyond ...
AbbVie’s $10.9B Apogee deal strengthens immunology beyond Humira, adds Zumilokibart optionality, and may be undervalued. See ...
Immunology is AbbVie's primary core competency. While the pharmaceutical company has successfully transitioned patients from Humira to its newer blockbusters, Skyrizi and Rinvoq, the Apogee ...
AbbVie said on Monday it would buy Apogee Therapeutics for $10.9 billion, the company's largest buyout in more than five years, as it seeks to bolster its treatment pipeline for inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results